Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

BACKGROUND: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Syversen, Unni, Stunes, Astrid K, Gustafsson, Björn I, Obrant, Karl J, Nordsletten, Lars, Berge, Rolf, Thommesen, Liv, Reseland, Janne E
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678137/
https://ncbi.nlm.nih.gov/pubmed/19331671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-9-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados